Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
ISRCTN |
Last refreshed on:
|
25 November 2019 |
Main ID: |
ISRCTN68133429 |
Date of registration:
|
28/02/2001 |
Prospective Registration:
|
No |
Primary sponsor: |
|
Public title:
|
A trial comparing conventional fractionation with 'CHART' in the treatment of head and neck cancer
|
Scientific title:
|
A trial comparing conventional fractionation with 'CHART' in the treatment of head and neck cancer |
Date of first enrolment:
|
01/01/1990 |
Target sample size:
|
500 |
Recruitment status: |
Completed |
URL:
|
http://isrctn.com/ISRCTN68133429 |
Study type:
|
Interventional |
Study design:
|
Randomised controlled trial (Not Specified)
|
Phase:
|
Not Specified
|
|
Countries of recruitment
|
United Kingdom
| | | | | | | |
Contacts
|
Name:
|
|
Address:
|
|
Telephone:
|
|
Email:
|
|
Affiliation:
|
|
|
Name:
|
James
Lyddiard |
Address:
|
MRC Clinical Trials Unit
222 Euston Road
NW1 2DA
London
United Kingdom |
Telephone:
|
- |
Email:
|
abc@email.com |
Affiliation:
|
|
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: 1. Histologically proven squamous cell carcinoma of all grades at one of the following sites: Nasal sinuses, Nasopharynx, Oral cavity, Oropharynx, Hypopharynx, Carcinoma of the larynx 2. A radical course of external beam radiotherapy is the appropriate sole treatment
Exclusion criteria: There should be no evidence of distant metastases beyond the regional nodes in the neck
Age minimum:
Age maximum:
Gender:
Not Specified
|
Health Condition(s) or Problem(s) studied
|
Cancer Cancer Head and neck
|
Intervention(s)
|
Conventional radiotherapy arm - 2 Gy, once daily five days a week over six weeks (large volume - 44 Gy in 22 fractions followed by small volume - 16 Gy in eight fractions)
CHART arm - 1.5 Gy, three time daily over 12 treatment days (large volume - 37.5 Gy in 25 fractions followed by small volume - 16.5 Gy in 11 fractions)
|
Primary Outcome(s)
|
1. Local tumour control 2. Survival 3. Morbidity
|
Secondary Outcome(s)
|
Not provided at time of registration
|
Source(s) of Monetary Support
|
Medical Research Council (MRC) (UK)
|
Ethics review
|
Status:
Approval date:
Contact:
Not provided at time of registration
|
Results
|
Results available:
|
Yes |
Date Posted:
|
|
Date Completed:
|
01/03/1995 |
URL:
|
|
|
|